Nymox Pharmaceutical Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced positive results from its newly completed long-term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). 26 clinical trial sites across the U.S. and 116 unselected subjects participated in the blinded, placebo controlled study.

MORE ON THIS TOPIC